Mito-apocynin (C11)

Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP) -based compound, is synthesized by conjugating the Apocynin moiety with a TPP+ cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function[1].

Product Specifications

CAS Number

[1254044-38-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Mitochondrial Metabolism

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/mito-apocynin-c11.html

Purity

99.84

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(OCCCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=C(O)C(OC)=C4.[Br-]

Molecular Formula

C37H44BrO4P

Molecular Weight

663.62

Precautions

H302, H315, H319, H335

References & Citations

[1]Dranka BP, et al. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2 (R1441G) ) transgenic mouse model of Parkinson's disease. Neurosci Lett. 2014 Nov 7;583:159-64.